Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10462224" target="_blank" >RIV/00064203:_____/23:10462224 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/23:10462224

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.22.01760" target="_blank" >10.1200/JCO.22.01760</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial

Popis výsledku v původním jazyce

PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m(2) every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS +- SE) and overall survival (OS +- SE) rates were 75.2% +- 0.6% and 82.6% +- 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% +- 1.4% and 94.7% +- 1.1%; IR (n = 4,111), 77.9% +- 0.7% and 85.7% +- 0.6%; and HR (n = 1,452), 60.8% +- 1.5% and 68.4% +- 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% +- 1.2% and 72.8% +- 1.2%, respectively (P = .55), while those in patients receiving MTX doses of 2 g/m(2) (n = 1,056) and MTX 5 g/m(2) (n = 1,027) were 78.8% +- 1.4% and 78.9% +- 1.4%, respectively (P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m(2) was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.

Název v anglickém jazyce

Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial

Popis výsledku anglicky

PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m(2) every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS +- SE) and overall survival (OS +- SE) rates were 75.2% +- 0.6% and 82.6% +- 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% +- 1.4% and 94.7% +- 1.1%; IR (n = 4,111), 77.9% +- 0.7% and 85.7% +- 0.6%; and HR (n = 1,452), 60.8% +- 1.5% and 68.4% +- 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% +- 1.2% and 72.8% +- 1.2%, respectively (P = .55), while those in patients receiving MTX doses of 2 g/m(2) (n = 1,056) and MTX 5 g/m(2) (n = 1,027) were 78.8% +- 1.4% and 78.9% +- 1.4%, respectively (P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m(2) was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Oncology

ISSN

0732-183X

e-ISSN

1527-7755

Svazek periodika

41

Číslo periodika v rámci svazku

19

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

3499-3511

Kód UT WoS článku

001037224100009

EID výsledku v databázi Scopus

2-s2.0-85161436569